Pasithea Therapeutics Corp. (KTTA) - מזומן למניה

Cash per share dynamics for Pasithea Therapeutics (KTTA) reflect the impact of research and development costs that constrain profits, offset by a moderate inflow from medical services. The 1.12 level captures the current state of liquidity while the market prices in R&D operating expenses in the absence of commercial sales. Growth potential is driven by the network of ketamine centers and an innovative approach to the therapy of PTSD and depression.
פילוחי מדדים מקיפים ואנליטיקה עבור Pasithea Therapeutics Corp (KTTA)

This indicator determines the volume of liquid assets per common share, measuring the issuer's actual financial strength. By analyzing actual cash per share via the GURU.Markets platform, an investor assesses the business's ability to fund the development of ALS therapies without emergency capital raises. For Pasithea Therapeutics (KTTA), this metric is critical due to the absence of current sales and high clinical trial costs. An optimal cash balance eliminates bankruptcy risk without creating excessive capital inefficiency. The trend of this indicator confirms the company's viability amid high market demand.